Gardasil Market Size, Trends and Insights By Type (Bivalent, Quadrivalent, Nonavalent), By Disease Indication (Cervical cancer, Anal cancer, Vulvar and vaginal cancer, Penile cancer, Oropharyngeal cancer, Genital warts), By Distribution Channel (Public sector, Private sector), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032


Report Code: CMI31878

Published Date: September 2023

Pages: 220+

Category: Pharmaceuticals

Report Snapshot

CAGR: 11.6%
3.9B
2022
4.7B
2023
11.9B
2032

Source: CMI

Study Period: 2023-2032
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sanofi Pasteur
  • Pfizer Inc.
  • CSL Limited
  • Novartis AG
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Gardasil Market is expected to record a CAGR of 11.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 3.9 billion. By 2032, the valuation is anticipated to reach USD 11.9 billion.

The Gardasil market constitutes the worldwide arena for vaccines formulated to combat human papillomavirus (HPV) infections. Gardasil, crafted by prominent pharmaceutical firms, provides a safeguard against diverse HPV strains, substantially mitigating the chances of cervical cancer and associated maladies.

The market’s essence lies in continual research, innovation, and vaccine manufacturing, accompanied by extensive education drives and immunization initiatives. Present-day developments encompass heightened attention to adolescent immunization, broader applications for Gardasil, and an escalating dedication to curbing HPV-related illnesses through extensive global vaccination campaigns.

Gardasil Market – Significant Growth Factors

The Gardasil Market presents significant growth opportunities due to several factors:

  • Growing Awareness: Increasing awareness about the importance of HPV vaccination in preventing cervical cancer is a significant driver. Educational campaigns and healthcare initiatives present opportunities for market growth.
  • Expanding Vaccination Programs: The expansion of vaccination programs, both in developed and developing countries, creates a larger customer base for Gardasil.
  • Rising HPV Infection Rates: The persistently high rates of HPV infections worldwide create a continuous demand for vaccines, driving market growth.
  • Emerging Markets: Emerging markets represent an untapped opportunity, with a rising middle-class population seeking access to preventive healthcare measures like Gardasil.
  • Advanced Formulations: Ongoing research and development efforts to improve vaccine formulations and delivery methods offer opportunities to enhance product efficacy and market competitiveness.
  • Global Disease Burden: The increasing global burden of HPV-related diseases, including various cancers, underscores the need for effective prevention, making Gardasil a critical player in addressing these health challenges.

Gardasil Market – Mergers and Acquisitions

The Gardasil Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their Type offerings and profitability. Some notable examples of mergers and acquisitions in the Gardasil Market include:

  • In July 2020, Merck made an announcement about the expanded approval granted by the USFDA for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). This extended approval included the prevention of oropharyngeal and other head and neck cancers attributed to HPV Types 16, 18, 31, 33, 45, 52, and 58.
  • In June 2020, in anticipation of the Global Vaccine Summit 2020, vaccine manufacturers like MSD, GSK, Innovax, Serum Institute of India Pvt. Ltd. (SII), and Walvax intensified their efforts to enhance the supply of HPV vaccines. These vaccines were targeted at Gavi-supported countries with notably high burdens of cervical cancer.
  • In January 2020, the Food and Drug Administration (FDA) implemented a noteworthy adjustment by raising the recommended age threshold for receiving the HPV vaccine to 45. This strategic move aimed to widen the accessibility of this crucial vaccine in the fight against human papillomavirus infections.

These mergers and acquisitions have helped companies expand their Type offerings, improve their market presence, and capitalize on growth opportunities in the Gardasil Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Gardasil Market Retail Pharmacy Market Biofilms Treatment Market
CAGR 11.6% (Approx) CAGR 7.1% (Approx) CAGR 7.6% (Approx)
USD 11.9 Billion by 2032 USD 1,215.4 Billion by 2032 USD 3.5 Billion by 2032

Gardasil Market – Significant Threats

The Gardasil Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Vaccine Hesitancy: Widespread vaccine hesitancy, fueled by misinformation and distrust in vaccines, can hamper the adoption of Gardasil and other HPV vaccines.
  • Competitive Landscape: Increasing competition from other HPV vaccines and potential new entrants could pose a threat to Gardasil’s market share.
  • Regulatory Challenges: Evolving regulatory requirements and safety concerns can affect vaccine approvals and market access.
  • Affordability and Accessibility: The cost of vaccination and limited access to healthcare in some regions may hinder widespread adoption.
  • Global Health Challenges: Events like pandemics and health crises can divert resources and attention away from HPV vaccination programs.
  • Evolving Disease Strains: As HPV strains evolve, vaccine effectiveness may be challenged, necessitating the development of updated formulations.
  • Reimbursement Issues: Challenges related to vaccine reimbursement and insurance coverage can affect patient access and market growth.
  • Public Health Priorities: Shifting public health priorities may impact funding and support for HPV vaccination initiatives.
  • Intellectual Property and Licensing: Legal disputes, licensing issues, and patent expirations can influence market dynamics.
  • Adverse Events and Safety Concerns: Reports of adverse events or safety concerns related to Gardasil can erode public trust and impact market demand.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 4.7 Billion
Projected Market Size in 2032 USD 11.9 Billion
Market Size in 2022 USD 3.9 Billion
CAGR Growth Rate 11.6% CAGR
Base Year 2022
Forecast Period 2023-2032
Key Segment By Type, Disease Indication, Distribution Channel and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Type:

  • Bivalent:  “Bivalent” in the Gardasil market refers to vaccines targeting two HPV strains. Trends include increasing adoption due to expanded indications, heightened focus on cervical cancer prevention, and the emergence of new bivalent HPV vaccines. Market competition and affordability remain key considerations in this niche segment.
  • Quadrivalent: Quadrivalent” signifies vaccines offering safeguarding against four designated strains of the human papillomavirus (HPV). Pertaining trends comprise the extension of vaccine coverage to shield against additional HPV strains, escalating rates of adolescent immunization, and concerted efforts to address vaccine hesitancy through robust educational campaigns. The objective is to effectively combat HPV-related diseases.
  • Nonavalent: Nonavalent refers to Gardasil 9, a human papillomavirus (HPV) vaccine targeting nine HPV types. In the Gardasil market, trends include expanded vaccine approvals for diverse HPV-related cancers, increased global access, and a focus on adolescent immunization. These trends aim to bolster HPV prevention and reduce associated diseases worldwide.

Global Gardasil Market 2023–2032 (By Billion)

www.custommarketinsight.com

By Disease indication

  • Cervical cancer: Cervical cancer, marked by malignant growth within the cervix, frequently linked to human papillomavirus (HPV), remains a pivotal focal point within the Gardasil market. Principal facets involve the expansion of vaccine applications, heightened and far-reaching public awareness initiatives, and the worldwide embrace of Gardasil to confront HPV-associated ailments, primarily concentrating on averting cervical cancer.
  • Anal cancer: Anal cancer, a rare malignancy impacting the anus, presents another noteworthy facet of the Gardasil market. A prominent trend involves expanding vaccine indications to encompass defense against HPV strains linked to anal cancer, indicating a broader outlook on HPV-related disease prevention.
  • Vulvar and vaginal cancer: Vulvar and vaginal cancer, affecting the external female genitalia and vaginal walls, witness a burgeoning trend within the Gardasil market. The vaccine’s effectiveness in thwarting HPV-related vulvar and vaginal cancers is propelling its adoption, bolstered by heightened awareness campaigns and extensive vaccination endeavors.
  • Penile cancer: Penile cancer, an uncommon malignancy afflicting the penis, experiences a rising tide in the Gardasil market. This evolving trend entails the widening of vaccine coverage to provide protection against HPV strains associated with penile cancer, demonstrating a comprehensive commitment to preventing HPV-related diseases, including those affecting males.
  • Oropharyngeal cancer: Oropharyngeal cancer, a specific type of head and neck cancer involving the throat, tonsils, and the base of the tongue, introduces a fascinating development within the Gardasil market. Of particular note is the expanded utility of the vaccine, aimed at preventing oropharyngeal and other head and neck cancers attributed to specific HPV strains such as Types 16, 18, 31, 33, 45, 52, and 58.
  • Genital warts: Genital warts, a sexually transmitted infection triggered by specific HPV strains, serve as a pivotal element in the Gardasil market. A significant trend revolves around the vaccine’s efficacy in thwarting HPV-related genital warts, underscoring its pivotal role in alleviating the burden associated with this condition. Additionally, the expansion of vaccination programs significantly contributes to the growth of this trend.

By Distribution Channel

  • Public sector: The public sector in the Gardasil market refers to government and government-funded healthcare organizations that play a vital role in vaccine distribution and immunization programs. Trends include increased government support for HPV vaccination campaigns, regulatory approvals for expanded age groups, and efforts to improve vaccine accessibility to underserved populations, contributing to market growth.
  • Private sector: The private sector in the Gardasil market refers to non-governmental organizations, pharmaceutical companies, and healthcare providers involved in vaccine production, distribution, and promotion. Current trends include increased partnerships between pharmaceutical firms and private healthcare providers, expanding access to Gardasil through private clinics, and targeted marketing efforts to boost vaccine adoption.

Global Gardasil Market 2023–2032 (By Distribution Channel)

www.custommarketinsight.com

Gardasil Market – Regional Analysis

The Gardasil Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America:  Within the Gardasil market, North America denotes the geographical expanse covering the United States and Canada. Pertinent trends within this domain encompass the proliferation of vaccination initiatives, the amplification of consciousness-raising endeavors, and the forging of strategic alliances with healthcare entities. Notably, the market has witnessed a transformative pivot towards more comprehensive adoption of HPV vaccines.
  • Europe: In the Gardasil market, Europe includes countries across the continent. Trends here involve growing acceptance of HPV vaccination, government-supported immunization programs, and rising HPV-related disease awareness, contributing to a steady market expansion.
  • Asia-Pacific: The Asia-Pacific Gardasil market includes nations in the region. Key trends comprise improving healthcare infrastructure, expanding access to vaccines in densely populated areas, and heightened focus on preventive healthcare, driving significant market growth.
  • LAMEA: In the Gardasil market, LAMEA encompasses regions such as Latin America, the Middle East, and Africa. Trends involve increasing investments in healthcare infrastructure, awareness campaigns to combat cervical cancer, and collaborations with global health organizations to enhance vaccine accessibility, all contributing to market development.

Global Gardasil Market 2023–2032 (By Type)

www.custommarketinsight.com

Competitive Landscape – Gardasil Market

The Gardasil Market is highly competitive, with a large number of manufacturers and others operating globally. Some of the key players in the market include:

  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sanofi Pasteur
  • Pfizer Inc.
  • CSL Limited
  • Novartis AG
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company Limited
  • Others

These companies operate in the market through various strategies such as application innovation, mergers and acquisitions, and partnerships.

Several new players have ventured into the Gardasil market by adopting innovative approaches and development strategies. These entrants focus on enhancing vaccine formulations, expanding geographical reach, and forging partnerships with healthcare providers.

While these newcomers are making strides, key players like Merck & Co., GlaxoSmithKline, and Sanofi Pasteur continue to dominate the Gardasil market. They leverage their extensive research capabilities, established distribution networks, and robust marketing efforts to maintain significant market share.

These dominant players also engage in ongoing research to broaden the vaccine’s indications, ensuring its continued relevance and prominence in cervical cancer prevention globally.

The Gardasil Market is segmented as follows:

By Type

  • Bivalent
  • Quadrivalent
  • Nonavalent

By Disease Indication

  • Cervical cancer
  • Anal cancer
  • Vulvar and vaginal cancer
  • Penile cancer
  • Oropharyngeal cancer
  • Genital warts

By Distribution Channel

  • Public sector
  • Private sector

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Gardasil Market, (2023 – 2032) (USD Billion)
    • 2.2 Global Gardasil Market : snapshot
  • Chapter 3. Global Gardasil Market – Industry Analysis
    • 3.1 Gardasil Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Growing Awareness
      • 3.2.2 Expanding Vaccination Programs
      • 3.2.3 Rising HPV Infection Rates
      • 3.2.4 Emerging Markets
      • 3.2.5 Advanced Formulations
      • 3.2.6 Global Disease Burden.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Type
      • 3.7.2 Market attractiveness analysis By Disease Indication
      • 3.7.3 Market attractiveness analysis By Distribution Channel
  • Chapter 4. Global Gardasil Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Gardasil Market: company market share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Gardasil Market – Type Analysis
    • 5.1 Global Gardasil Market overview: By Type
      • 5.1.1 Global Gardasil Market share, By Type, 2022 and 2032
    • 5.2 Bivalent
      • 5.2.1 Global Gardasil Market by Bivalent , 2023 – 2032 (USD Billion)
    • 5.3 Quadrivalent
      • 5.3.1 Global Gardasil Market by Quadrivalent , 2023 – 2032 (USD Billion)
    • 5.4 Nonavalent
      • 5.4.1 Global Gardasil Market by Nonavalent, 2023 – 2032 (USD Billion)
  • Chapter 6. Global Gardasil Market – Disease Indication Analysis
    • 6.1 Global Gardasil Market overview: By Disease Indication
      • 6.1.1 Global Gardasil Market share, By Disease Indication, 2022 and 2032
    • 6.2 Cervical cancer
      • 6.2.1 Global Gardasil Market by Cervical cancer, 2023 – 2032 (USD Billion)
    • 6.3 Anal cancer
      • 6.3.1 Global Gardasil Market by Anal cancer, 2023 – 2032 (USD Billion)
    • 6.4 Vulvar and vaginal cancer
      • 6.4.1 Global Gardasil Market by Vulvar and vaginal cancer, 2023 – 2032 (USD Billion)
    • 6.5 Penile cancer
      • 6.5.1 Global Gardasil Market by Penile cancer, 2023 – 2032 (USD Billion)
    • 6.6 Oropharyngeal cancer
      • 6.6.1 Global Gardasil Market by Oropharyngeal cancer, 2023 – 2032 (USD Billion)
    • 6.7 Genital warts
      • 6.7.1 Global Gardasil Market by Genital warts, 2023 – 2032 (USD Billion)
  • Chapter 7. Global Gardasil Market – Distribution Channel Analysis
    • 7.1 Global Gardasil Market overview: By Distribution Channel
      • 7.1.1 Global Gardasil Market share, By Distribution Channel, 2022 and 2032
    • 7.2 Public sector
      • 7.2.1 Global Gardasil Market by Public sector, 2023 – 2032 (USD Billion)
    • 7.3 Private sector
      • 7.3.1 Global Gardasil Market by Private sector, 2023 – 2032 (USD Billion)
  • Chapter 8. Gardasils Industry – Regional Analysis
    • 8.1 Global Gardasils Industry Regional Overview
    • 8.2 Global Gardasils Industry Share, by Region, 2022 & 2032 (USD Billion)
    • 8.3. North America
      • 8.3.1 North America Gardasils Industry, 2023 – 2032 (USD Billion)
        • 8.3.1.1 North America Gardasils Industry, by Country, 2023 – 2032 (USD Billion)
    • 8.4 North America Gardasils Industry, by Type, 2023 – 2032
      • 8.4.1 North America Gardasils Industry, by Type, 2023 – 2032 (USD Billion)
    • 8.5 North America Gardasils Industry, by Disease Indication, 2023 – 2032
      • 8.5.1 North America Gardasils Industry, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.6 North America Gardasils Industry, by Distribution Channel, 2023 – 2032
      • 8.6.1 North America Gardasils Industry, by Distribution Channel, 2023 – 2032 (USD Billion)
    • 8.7. Europe
      • 8.7.1 Europe Gardasils Industry, 2023 – 2032 (USD Billion)
        • 8.7.1.1 Europe Gardasils Industry, by Country, 2023 – 2032 (USD Billion)
    • 8.8 Europe Gardasils Industry, by Type, 2023 – 2032
      • 8.8.1 Europe Gardasils Industry, by Type, 2023 – 2032 (USD Billion)
    • 8.9 Europe Gardasils Industry, by Disease Indication, 2023 – 2032
      • 8.9.1 Europe Gardasils Industry, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.10 Europe Gardasils Industry, by Distribution Channel, 2023 – 2032
      • 8.10.1 Europe Gardasils Industry, by Distribution Channel, 2023 – 2032 (USD Billion)
    • 8.11. Asia Pacific
      • 8.11.1 Asia Pacific Gardasils Industry, 2023 – 2032 (USD Billion)
        • 8.11.1.1 Asia Pacific Gardasils Industry, by Country, 2023 – 2032 (USD Billion)
    • 8.12 Asia Pacific Gardasils Industry, by Type, 2023 – 2032
      • 8.12.1 Asia Pacific Gardasils Industry, by Type, 2023 – 2032 (USD Billion)
    • 8.13 Asia Pacific Gardasils Industry, by Disease Indication, 2023 – 2032
      • 8.13.1 Asia Pacific Gardasils Industry, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.14 Asia Pacific Gardasils Industry, by Distribution Channel, 2023 – 2032
      • 8.14.1 Asia Pacific Gardasils Industry, by Distribution Channel, 2023 – 2032 (USD Billion)
    • 8.15. Latin America
      • 8.15.1 Latin America Gardasils Industry, 2023 – 2032 (USD Billion)
        • 8.15.1.1 Latin America Gardasils Industry, by Country, 2023 – 2032 (USD Billion)
    • 8.16 Latin America Gardasils Industry, by Type, 2023 – 2032
      • 8.16.1 Latin America Gardasils Industry, by Type, 2023 – 2032 (USD Billion)
    • 8.17 Latin America Gardasils Industry, by Disease Indication, 2023 – 2032
      • 8.17.1 Latin America Gardasils Industry, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.18 Latin America Gardasils Industry, by Distribution Channel, 2023 – 2032
      • 8.18.1 Latin America Gardasils Industry, by Distribution Channel, 2023 – 2032 (USD Billion)
    • 8.19. The Middle-East and Africa
      • 8.19.1 The Middle-East and Africa Gardasils Industry, 2023 – 2032 (USD Billion)
        • 8.19.1.1 The Middle-East and Africa Gardasils Industry, by Country, 2023 – 2032 (USD Billion)
    • 8.20 The Middle-East and Africa Gardasils Industry, by Type, 2023 – 2032
      • 8.20.1 The Middle-East and Africa Gardasils Industry, by Type, 2023 – 2032 (USD Billion)
    • 8.21 The Middle-East and Africa Gardasils Industry, by Disease Indication, 2023 – 2032
      • 8.21.1 The Middle-East and Africa Gardasils Industry, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.22 The Middle-East and Africa Gardasils Industry, by Distribution Channel, 2023 – 2032
      • 8.22.1 The Middle-East and Africa Gardasils Industry, by Distribution Channel, 2023 – 2032 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1 Merck & Co. Inc.
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 GlaxoSmithKline plc
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 Sanofi Pasteur
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Pfizer Inc.
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 CSL Limited
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 Novartis AG
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 AstraZeneca plc
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Johnson & Johnson
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 Takeda Pharmaceutical Company Limited
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 Daiichi Sankyo Company Limited
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments
    • 9.11 Others.
      • 9.11.1 Overview
      • 9.11.2 Financials
      • 9.11.3 Product Portfolio
      • 9.11.4 Business Strategy
      • 9.11.5 Recent Developments
List Of Figures

Figures No 1 to 27

List Of Tables

Tables No 1 to 77

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sanofi Pasteur
  • Pfizer Inc.
  • CSL Limited
  • Novartis AG
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company Limited
  • Others

FAQs

The key factors driving the Market are Growing Awareness, Expanding Vaccination Programs, Rising HPV Infection Rates, Emerging Markets, Advanced Formulations And Global Disease Burden.

The “Disease Indication” category dominated the market in 2022.

The key players in the market are Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur, Pfizer Inc., CSL Limited, Novartis AG, AstraZeneca plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Others.

“Europe” had the largest share in the Gardasil Market.

The global market is projected to grow at a CAGR of 11.6% during the forecast period, 2023-2032.

The Gardasil Market size was valued at USD 3.9 Billion in 2022.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!